Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Cell Therapy News 18.07 March 6, 2017 | |
 | |
| |
TOP STORYScientists identified glucocorticoid (GC) hormone signaling as an activator of CXCR4 expression in human cord blood (CB) hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). Short-term GC pretreatment of human CB HSCs and HPCs promoted SDF-1–CXCR4-axis-mediated chemotaxis, homing, and long-term engraftment when these cells were transplanted into primary- and secondary-recipient NSG mice. [Nat Med] Abstract | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors evaluated the potential of targeting a small molecule inhibitor of transforming growth factor-β (TGF-β) to adoptive cell therapy T-cells using PEGylated immunoliposomes. When administered i.v. to target T-cells in vivo, only targeting of a CD90 isoform expressed exclusively by the donor T-cells led to greater tumor regression over equivalent doses of free systemic drug. [ACS Nano] Abstract | Graphical Abstract Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy Researchers proposed a multifunctional envelope-type nanoparticle (NP) platform for prostate cancer-specific in vivo siRNA delivery. A library of oligoarginine-functionalized and sharp pH-responsive polymers was synthesized and used for self-assembly with siRNA into NPs with the features of long blood circulation and pH-triggered oligoarginine-mediated endosomal membrane penetration. [ACS Nano] Abstract | Graphical Abstract The authors compared three chimeric antigen receptor (CAR) T-cell termination strategies: (1) transiently-active anti-CD123 mRNA-electroporated CART, (2) T-cell ablation with alemtuzumab after treatment with lentivirally-transduced anti-CD123-4-1BB-CD3ζ T-cells, and (3) T-cell ablation with rituximab after treatment with CD20-coexpressing CART123. [Blood] Abstract Engineering a Humanized Bone Organ Model in Mice to Study Bone Metastases Additive biomanufactured scaffolds seeded and cultured with human bone-forming cells were implanted ectopically in combination with osteogenic factors into mice to generate a physiological bone ‘organ’, which is partially humanized. The model comprised of human bone cells and secreted extracellular matrix; however, other components of the engineered tissue, such as the vasculature, were of murine origin. [Nat Protoc] Abstract The authors engrafted familial hypercholesterolemia hepatocytes into the liver of Ldlr−/−/Rag2−/−/Il2rg−/− mice, and assessed the effect of these same medications on low-density lipoprotein cholesterol clearance and endothelium-dependent vasodilation in vivo. [Stem Cell Reports] Full Article | Graphical Abstract Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives The authors examined the efficacy of the inducible caspase-9 (iCaspase9) gene as a fail-safe against undesired tumorigenic transformation of induced pluripotent stem cells (iPSCs)-derived somatic cells. They used a lentiviral vector to transduce iCaspase9 into two iPSC lines and assessed its efficacy in vitro and in vivo. [Stem Cell Reports] Full Article Researchers used a collagen-based biomaterial, named the NeuroRegen scaffold, loaded with human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in a canine chronic spinal cord injury (SCI) model. To generate chronic SCI, the T8 spinal cord segment was removed by complete transection of the spinal cord. Two months later, glial scar tissue was removed and a NeuroRegen scaffold was transplanted into the lesion area. [Sci Rep] Full Article Human Eyelid Adipose Tissue-Derived Schwann Cells Promote Regeneration of a Transected Sciatic Nerve To explore whether human eyelid adipose-derived Schwann cells (hE-SCs) promote the regeneration of injured peripheral nerves in vivo, a Balb/c-nu mice model was used. Mice were randomly assigned to five groups: Matrigel; hE-SCs/P0; hE-SCs/P2; hE-FLCs/P2; and Autograft. After 12 weeks, functional and histological assessments of the regenerated nerves showed that sciatic nerve defect was more effectively repaired in the hE-SCs/P2 group which achieved 66.1 ± 6.5% purity, than the other three groups and recovered to similar level to the Autograft group. [Sci Rep] Full Article Researchers investigated a novel, simple methodology for using adenovirus transfer to target specific cells of the kidney tubules for the expression of exogenous proteins. They selected genes encoding sodium-dependent phosphate transporter type 2a in the proximal tubule, sodium-potassium-2-chloride cotransporter in the thick ascending limb of Henle, and aquaporin 2 in the collecting duct. [PLoS One] Full Article | |
| |
| |
REVIEWSA systematic literature review was performed using MEDLINE, Cochrane Library and EMBASE. It includes outcomes observed in in vitro analyses, in vivo animal studies and clinical studies. Data from basic science work have been included in the discussion to enhance understanding of the mechanism behind adipose-derived stem cell behavior. [Stem Cell Res Ther] Full Article Visit our reviews page to see a complete list of reviews in the cell therapy research field. | |
| |
| |
SCIENCE NEWSMaxCyte to Present Pre-Clinical CARMA Data MaxCyte announced it will present results of pre-clinical in vivo research demonstrating the potential of its novel, proprietary, CARMA platform for use in developing immunotherapies for the treatment of solid tumors. [Press release from MaxCyte discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting, Washington, DC] Press Release | |
| |
| |
INDUSTRY NEWSGenomeDx Biosciences announced the initiation of a prospective, randomized controlled trial evaluating the utility of GenomeDx’s Decipher® Prostate Cancer Classifier, a commercially available genomic test that examines the activity of genes in prostate cancer cells and estimates the likelihood that a patient’s cancer will metastasize. [GenomeDx Biosciences] Press Release John Theurer Cancer Center (JTCC) at Hackensack University Medical Center was part of this critical large multi-center study which confirmed the activity of this groundbreaking approach. For almost a decade JTCC has been involved in novel cellular therapies to improve the outcome of patients with blood cancers, working with the NCI and Kite Pharma, which is seeking FDA approval for the therapy. [Hackensack Meridian Health (PR Newswire Association LLC.)] Press Release Johns Hopkins Medicine, the Maryland Stem Cell Research Fund and BioCardia, Inc. announced that the first patient has been treated in the pivotal Phase III CardiAMP® clinical trial of a cell-based therapy for the treatment of ischemic heart failure that develops after a heart attack. [Johns Hopkins Medicine (Business Wire, Inc.)] Press Release ImmunoCellular announced successful completion of the first milestone for the company’s Stem-to-T-cell program, the sequencing of a selected T cell receptor (TCR) gene. When inserted into a blood stem cell, this TCR gene is expected to enhance patients’ immune systems to produce killer T cells programmed to attack tumors. This Stem-to-T-cell therapeutic strategy has the potential to provide a safer, sustainable and more specific immune treatment for cancer. [ImmunoCellular Therapeutics, Ltd.] Press Release Gamida Cell announced that the first patient has been transplanted in the company’s Phase III study of NiCord®, in development as a cure for patients with blood cancer who do not have a fully matched donor required for bone marrow transplantation, a potentially $3 billion market. NiCord has an FDA Breakthrough Therapy Designation as well as FDA and EMA orphan drug designations. [Gamida Cell] Press Release SELLAS Life Sciences Group reported updated positive Phase II data from its WT1 immunotherapeutic anti-cancer treatment, galinpepimut-S, in multiple myeloma patients. [SELLAS Life Sciences Group] Press Release Sangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-913, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type II (MPS II), a rare lysosomal storage disorder. [Sangamo Therapeutics, Inc.] Press Release Natera, Inc. Announces Launch of Evercordâ„¢ Cord Blood and Tissue Banking Service Natera announced the upcoming launch of Evercord; a new offering being made commercially available in the second quarter of 2017 that enables expectant parents to collect, store and potentially retrieve their newborn’s cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications. [Natera, Inc.] Press Release | |
| |
POLICY NEWSGovernment of Canada Celebrates Cutting-Edge Infrastructure for Researchers at Ryerson University The Honorable Bill Morneau, Minister of Finance, on Behalf of the Honorable Kirsty Duncan, Minister of Science Celebrated $128,000 in Funding for Ryerson University. [Government of Canada] Editorial What Trump’s New Travel Ban Means for Science US President Donald Trump has signed a revised version of his controversial travel ban. The policy, issued on 6th March, exempts citizens of Iraq and people who have already been issued US visas — including those with green cards. Like the first order, which Trump signed on 27th January, the revised policy bars citizens of Iran, Libya, Somalia, Sudan, Syria and Yemen from the US for 90 days. [Nature News] Editorial EU and FDA Agree to Ditch Duplication of Drug Manufacturer GMP Inspections Drug makers in the EU and U.S. may no longer be required to undergo separate GMP inspections by the FDA and the competent authorities in EU member states following an agreement by the EU and U.S. regulators to recognize each other’s inspections of pharmaceutical manufacturing sites within their own territories. [Genetic Engineering & Biotechnology News] Editorial
| |
REGULATORYFDAIssuance of Priority Review Voucher; Rare Pediatric Disease Product (FR Doc. No:2017-04228) Notice DSM Biomedical; Filing of Color Additive Petition (FR Doc. No:2017-04188) Notice Gastroenterology-Urology Devices; Manual Gastroenterology-Urology Surgical Instruments and Accessories (FR Doc. No:2017-03997) Notice
| |
EVENTSNEW ESMO Symposium on Signaling Pathways in Cancer 2017 NEW Keystone Symposium: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology NEW 4th Immunotherapy of Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Scientist – Immunotherapies for Cancer (GammaDelta Therapeutics Limited) Associate/Full Professor – Loretta Rogers Chair in Immunobioengineering (University of Toronto) Medical Director – Clinical Research Physician (Celgene Corporation) Postdoctoral Fellow – Various Projects (University of Oklahoma) GMP Manufacturing Director – Cell and Gene Therapy (Fred Hutchinson Cancer Research Center) Assistant Professor – Molecular Therapeutics of Cancer (Dartmouth College) Assistant or Associate Member – Stem CellGene Therapy (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cell Therapy News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Cell Therapy News Volume 18.07 | Mar 6 2017
